Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net loss	$ (39,615)	$ (27,978)	$ (40,531)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Share-based compensation expense	3,371	5,001	2,406
Change in fair value of contingent consideration liability	39,913	(1,900)	4,000
Recognition of right to borrow asset	(2,800)
Amortization of debt discount, deferred interest and right to borrow asset	1,079	447	602
Amortization of discount on available-for-sale securities		1	204
Depreciation	3,323	4,336	4,432
(Gain)/loss on disposal of property and equipment	(15)	(415)
Changes in operating assets and liabilities:
Receivables	(129)	10,000	(10,000)
Inventory	(3,447)
Prepaid expenses and other current assets	(601)	(203)	316
Other assets		200	(147)
Accounts payable	1,642	(1,456)	822
Accrued clinical trial expense and other accrued liabilities	1,122	559	(498)
Deferred revenues	(2,916)	(2,618)	6,303
Other liabilities	(1,539)	(4,215)	(2,335)
Net cash used in operating activities	(612)	(18,241)	(34,426)
Cash flows from investing activities:
Purchase of available-for-sale securities	(19,227)		(28,465)
Maturities of available-for-sale securities	10,650	2,000	54,036
Purchases of property and equipment	(1,784)	(452)	(496)
Proceeds from disposal of property and equipment	16	425
Net cash provided by (used in) investing activities	(10,345)	1,973	25,075
Cash flows from financing activities:
Proceeds from issuance of common stock, common stock warrants and exercise of stock options and stock purchase rights	6,583	35,242	16,145
Payment of contingent payment to Symphony Allegro Holdings, LLC	(10,313)	(5,000)
Change in current restricted cash	5,051	(5,051)
Proceeds from term loans	15,000
Payments of term loans	(5,773)	(6,110)	(5,563)
Net cash provided by financing activities	10,548	19,081	10,582
Net increase (decrease) in cash and cash equivalents	(409)	2,813	1,231
Cash and cash equivalents at beginning of period	17,715	14,902	13,671
Cash and cash equivalents at end of period	17,306	17,715	14,902
Supplemental disclosures of cash flow information
Cash paid for interest	863	979	1,631
Non cash investing and financing activities:
Debt discount related to Teva Note	4,405
Reversal of Note Payable to Autoliv			$ 1,200